Bugworks Research Inc., a clinical stage biopharmaceutical company, and Cytecare Cancer Hospitals announced the launch of a first-of-its-kind collaboration. Bugworks develops best-in-class, novel therapies...
ACT Sciences, Addiction Cure Therapeutic Sciences Inc an international Rx solution company targeting drug and alcohol addiction cures and treatments, announced it has begun...
The Rare Disease Cures Accelerator-Data and Analytics Platform initiative (RDCA-DAP®) hosted an all-day workshop and annual meeting September 13 and 14 in Washington. The...
Neuron23™ Inc., an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, and QIAGEN ( NYSE: QGEN;...
